Biomea Fusion, Inc.

NASDAQ:BMEA

Biotechnology

Healthcare
$0.74 -2.50%

-$0.03 today

Market cap
$53.18M
Beta
-0.33
P/E (TTM)
-1.9
EPS (TTM)
-$0.62
52W Low $0.87High $2.99

Volume 3.50M

Average 1.52M

BMEA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Biomea Fusion, Inc.NASDAQ: BMEA

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How BMEA compares with its peers on the latest reported figures

  • BMEA's LTM Mar 2026 revenue of $0 is the 4th highest of the 9 companies compared; the peer median is $0.
BMEA Competitors Peer median
Revenue for BMEA and competitors
Company Period LTM YoY 3-year CAGR
STROSutro Biopharma, Inc.LTM Mar 2026$99.61M +49.9%+14.8%
CBUSCibus, Inc.LTM Mar 2026$4.29M -9.8%+185.1%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$3.93M +160.5%—
BMEABiomea Fusion, Inc.LTM Mar 2026$0 ——
ALXOALX Oncology Holdings Inc.LTM Mar 2026$0 ——
IMUXImmunic, Inc.LTM Mar 2026$0 ——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$0 ——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 ——
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 -100.0%—
Peer median (excluding BMEA) $0+20.1%+100.0%

Competitors are the stored peer set for BMEA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00001.41M
Gross Profit0000(1.41M)
Gross Margin—————
Research & Development28M62.71M102.55M118.09M61.98M
Selling, General & Admin13.67M20.92M23.59M25.99M19.33M
Operating Expenses41.67M83.63M126.14M144.07M79.9M
Depreciation & Amortization249K691K1.52M1.75M1.41M
EBITDA(41.32M)(81.14M)(115.74M)(136.68M)(60.39M)
EBITDA Margin—————
Operating Income(41.67M)(83.63M)(126.14M)(144.07M)(81.31M)
Operating Margin—————
Interest Income100K1.81M8.88M5.64M1.86M
Interest Expense00000
Other Income / Expenses100K1.81M8.88M5.64M19.51M
Income Before Tax(41.57M)(81.83M)(117.26M)(138.43M)(61.8M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(41.57M)(81.83M)(117.26M)(138.43M)(61.8M)
Net Margin—————
EPS (Basic)(1.74)(2.80)(3.44)(3.83)(1.18)
EPS (Diluted)(1.74)(2.80)(3.44)(3.83)(1.18)
Weighted Avg Shares23.86M29.27M34.11M36.11M52.23M
Weighted Avg Shares (Diluted)23.86M29.27M34.11M36.11M52.23M

Biomea Fusion, Inc.

NASDAQ:BMEA

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.